Crisnatol mesylate | BWA770U | BWA-770U | CAS#96389-69-4 | 96389-68-3 | DNA intercalator

MedKoo Cat#: 206728 | Name: Crisnatol mesylate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Crisnatol, also known as BWA770U, is a potent and selective DNA intercalator with potential anticancer activity. Crisnatol entered into phase I and II clinical trials. It was discontinued now.

Chemical Structure

Crisnatol mesylate

CAS#96389-69-4 (mesylate)

Theoretical Analysis

MedKoo Cat#: 206728

Name: Crisnatol mesylate

CAS#: 96389-69-4 (mesylate)

Chemical Formula: C24H25NO4S

Exact Mass:

Molecular Weight: 423.53

Elemental Analysis: C, 68.06; H, 5.95; N, 3.31; O, 15.11; S, 7.57

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

96389-68-3(free base) 96389-69-4 (mesylate)

Synonym

770U-82 mesylate; BW-A-770U mesylate; 770U-82; BW-770; BW-77OU-82; BW-A-770U; Crisnatol mesylate.

IUPAC/Chemical Name

2-((chrysen-6-ylmethyl)amino)-3-hydroxy-2-methylpropyl methanesulfonate

InChi Key

MXEVUFSATVKQQG-UHFFFAOYSA-N

InChi Code

InChI=1S/C24H25NO4S/c1-24(15-26,16-29-30(2,27)28)25-14-18-13-23-19-8-4-3-7-17(19)11-12-22(23)21-10-6-5-9-20(18)21/h3-13,25-26H,14-16H2,1-2H3

SMILES Code

OCC(C)(NCC1=C2C=CC=CC2=C3C(C4=CC=CC=C4C=C3)=C1)COS(C)(=O)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Related CAS# CAS No. 96389-68-3(Crisnatol) 96389-69-4(Crisnatol mesylate)

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 423.53 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Villalona-Calero MA, Petit T, Kuhn J, Cobb P, Kraynak M, Eckhardt SG, Drengler R, Simmons C, Santabarbara P, Von Hoff DD, Rowinsky EK. A phase I and pharmacological study of protracted infusions of crisnatol mesylate in patients with solid malignancies. Clin Cancer Res. 1999 Nov;5(11):3369-78. PubMed PMID: 10589747. 2: Dorr RT, Bellamy W, Liddil JD, Baker A, Bair KW. Correlation of cytotoxicity and protein-associated DNA strand breaks for 2-(arylmethylamino)-1,3-propanediols. Anticancer Drug Des. 1998 Oct;13(7):825-35. PubMed PMID: 9807165. 3: New P, Vokes E, Rogers L, Bazan C, Hohneker J, Eble M, Vilk P. Long-term response to crisnatol mesylate in patients with glioma. Invest New Drugs. 1997;15(4):343-52. PubMed PMID: 9547677. 4: Bailey H, Kohler P, Tuttle R, Carbone PP, Hohneker JA, Clendeninn NJ, Wilding G. Phase I evaluation of 773U82-HCl in a two-hour infusion repeated daily for three days. Invest New Drugs. 1992 Nov;10(4):279-87. PubMed PMID: 1487401. 5: Smalley RV, Goldstein D, Bulkowski D, Hannon C, Buchler D, Knudsen C, Tuttle RL. A phase II study of crisnatol mesylate in patients with ovarian carcinoma. Invest New Drugs. 1992 Jul;10(2):107-12. PubMed PMID: 1500264. 6: Hufford CD, el-Sharkawy SH, Jurgens TM, Mikell JR. Microbial production of a crisnatol metabolite. Pharm Res. 1992 May;9(5):623-5. PubMed PMID: 1608892. 7: Zucker RM, Adams DJ, Bair KW, Elstein KH. An efficient multiple-exposure analysis of the toxicity of crisnatol, a DNA intercalator in phase II clinical trials. Invest New Drugs. 1992 Apr;10(1):1-15. PubMed PMID: 1607248. 8: Zucker RM, Adams DJ, Bair KW, Elstein KH. Polyploidy induction as a consequence of topoisomerase inhibition. A flow cytometric assessment. Biochem Pharmacol. 1991 Nov 6;42(11):2199-208. PubMed PMID: 1659821. 9: Patel DK, Shockcor JP, Chang SY, Sigel CW, Huber BE. Metabolism of a novel antitumor agent, crisnatol, by a human hepatoma cell line, Hep G2, and hepatic microsomes. Characterization of metabolites. Biochem Pharmacol. 1991 Jul 5;42(2):337-46. PubMed PMID: 1650211. 10: Bair KW, Andrews CW, Tuttle RL, Knick VC, Cory M, McKee DD. 2-[(arylmethyl) amino]-2-methyl-1,3-propanediol DNA intercalators. An examination of the effects of aromatic ring variation on antitumor activity and DNA binding. J Med Chem. 1991 Jul;34(7):1983-90. PubMed PMID: 2066971. 11: Carter CA, Bair KW. Effects of isomeric 2-(arylmethylamino)-1,3-propanediols (AMAPs) and clinically established agents on macromolecular synthesis in P388 and MCF-7 cells. Invest New Drugs. 1991 May;9(2):125-36. PubMed PMID: 1874597. 12: Patel DK, Woolley JL Jr, Shcokcor JP, Johnson RL, Taylor LC, Sigel CW. Disposition, metabolism, and excretion of the anticancer agent crisnatol in the rat. Drug Metab Dispos. 1991 Mar-Apr;19(2):491-7. PubMed PMID: 1676660. 13: Poplin EA, Chabot GG, Tuttle RL, Lucas S, Wargin WA, Baker LH. Crisnatol mesylate: phase I dose escalation by extending infusion duration. Invest New Drugs. 1991 Feb;9(1):41-7. PubMed PMID: 2026483. 14: Cobb PW, Havlin KA, Kuhn JG, Craig JB, Harman GS, Luther JS, Turner JN, Weiss GR, Tweedy DA, Koeller J, et al. Phase I evaluation of crisnatol (BWA770U mesylate) on a monthly extended infusion schedule. Sel Cancer Ther. 1991 Summer;7(2):85-91. PubMed PMID: 1754731. 15: Brown TD, Burris HA, Havlin KA, O'Rourke TJ, Rodriguez GI, Wall JG, Weiss GR. New anticancer agents. Cancer Chemother Biol Response Modif. 1991;12:111-46. Review. PubMed PMID: 1718374. 16: Bair KW, Tuttle RL, Knick VC, Cory M, McKee DD. (1-Pyrenylmethyl)amino alcohols, a new class of antitumor DNA intercalators. Discovery and initial amine side chain structure-activity studies. J Med Chem. 1990 Sep;33(9):2385-93. PubMed PMID: 2391683. 17: Adams DJ, Watkins PJ, Knick VC, Tuttle RL, Bair KW. Evaluation of arylmethylaminopropanediols by a novel in vitro pharmacodynamic assay: correlation with antitumor activity in vivo. Cancer Res. 1990 Jun 15;50(12):3663-9. PubMed PMID: 2340515. 18: Adams DJ. In vitro pharmacodynamic assay for cancer drug development: application to crisnatol, a new DNA intercalator. Cancer Res. 1989 Dec 1;49(23):6615-20. PubMed PMID: 2819712. 19: Massaro EJ, Elstein KH, Zucker RM, Bair KW. Limitations of the fluorescent probe viability assay. Mol Toxicol. 1989 Oct-Dec;2(4):271-84. PubMed PMID: 2490980. 20: Harman GS, Craig JB, Kuhn JG, Luther JS, Turner JN, Weiss GR, Tweedy DA, Koeller J, Tuttle RL, Lucas VS, et al. Phase I and clinical pharmacology trial of crisnatol (BWA770U mesylate) using a monthly single-dose schedule. Cancer Res. 1988 Aug 15;48(16):4706-10. PubMed PMID: 3396016.